Information Provided By: 
Fly News Breaks for February 29, 2016
VVUS
Feb 29, 2016 | 08:41 EDT
As noted earlier, RBC Capital downgraded VIVUS to Sector Perform from Outperform. The firm says that it expects the company's obesity drug, Qsymia, to have difficulty gaining market share because of the lack of enthusiasm for anti-obesity drugs among doctors and payers in the U.S. Target to $1 from $4.
News For VVUS From the Last 2 Days
There are no results for your query VVUS
